---
title: "Using Antihypertensive Medication Fill Histories to Improve Cardiovascular Risk Prediction"
id: "medrxiv-18-digital-treatment-signatures-cardiovascular-risk-prediction-using"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-18-digital-treatment-signatures-cardiovascular-risk-prediction-using"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.03.26362175v1?rss=1"
published_at: "2026-09-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Using Antihypertensive Medication Fill Histories to Improve Cardiovascular Risk Prediction
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-18-digital-treatment-signatures-cardiovascular-risk-prediction-using
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.03.26362175v1?rss=1)
- **Published At:** 2026-09-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study analyzed linked electronic health record and pharmacy dispensing data for 7,625 adults treated for hypertension to test whether longitudinal dispensing patterns add prognostic value beyond standard summaries. - Researchers compared conventional proportion of days covered (**PDC**), engineered temporal and regimen summary features, and the full ordered fill sequence modeled with an attention-based bidirectional LSTM survival network. - Predictions targeted a composite outcome of 3-year myocardial infarction, stroke, or all-cause death using a 1-year medication-history window and fixed cohort, covariates, horizon, and validation approach. - Discrimination (C-index) rose stepwise: clinical factors alone 0.7113; plus PDC 0.7131; engineered summaries 0.7273; and the ordered sequence 0.7396 (ΔC=0.0283; 95% CI, 0.0189–0.0382). - The sequence model outperformed engineered summaries by 0.0123 (95% CI, 0.0040–0.0202). Representation richness improved discrimination by ~0.0181–0.0191, while changing model class accounted for ~0.0059–0.0078. - Among patients with PDC ≥0.80, PDC poorly ranked risk (C=0.4628), but the sequence-model strata had wide 3-year event rates (3.6%–22.8%), indicating substantial masked heterogeneity. - Authors conclude that a tokenized dispensing timeline preserves temporal structure that aggregate adherence measures discard; this recovered “treatment signatures” improve cardiovascular risk prediction from existing records. - The study notes the need for external validation. Data are not publicly available due to protected health information, but de-identified analytic datasets may be available to qualified researchers under institutional approval and data-use agreements. - Ethical approval was granted by the University of Michigan Medical School IRB (HUM00244597) with a waiver of informed consent. One author disclosed a one-time advisory board role with Boehringer Ingelheim; other authors declared no competing interests.
## Clinical Analysis & Structured Key Points
Digital Treatment Signatures: Cardiovascular Risk Prediction Using Antihypertensive Medication Fill History | medRxiv Skip to main content Digital Treatment Signatures: Cardiovascular Risk Prediction Using Antihypertensive Medication Fill History Yifan Zheng , View ORCID Profile Karen B. Farris , Antoinette B. Coe , View ORCID Profile Michael P. Dorsch , View ORCID Profile Kayvan Najarian , Corey A. Lester doi: https://doi.org/10.64898/2026.09.03.26362175 Yifan Zheng 1 Department of Clinical Pharmacy Translational Science, College of Pharmacy, University of Michigan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: yifzheng{at}umich.edu Karen B. Farris 1 Department of Clinical Pharmacy Translational Science, College of Pharmacy, University of Michigan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Karen B. Farris Antoinette B. Coe 1 Department of Clinical Pharmacy Translational Science, College of Pharmacy, University of Michigan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael P. Dorsch 1 Department of Clinical Pharmacy Translational Science, College of Pharmacy, University of Michigan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Michael P. Dorsch Kayvan Najarian 2 Department of Computational Medicine and Bioinformatics, Medical School, University of Michigan Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kayvan Najarian Corey A. Lester 1 Department of Clinical Pharmacy Translational Science, College of Pharmacy, University of Michigan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Objective: Taking a blood pressure medication is not a single fact but a trajectory of fills, gaps, and regimen changes. Dispensing records capture that trajectory, yet risk calculators reduce it to a yes/no treatment indicator and quality programs to proportion of days covered (PDC). We asked how much of that discarded signal is recoverable. Materials and Methods: We studied 7,625 adults treated for hypertension using linked electronic health record and pharmacy dispensing data. From a 1-year medication-history window, we predicted 3-year myocardial infarction, stroke, or all-cause death. Holding cohort, covariates, horizon, and validation fixed, we compared PDC, engineered temporal and regimen features, and the ordered fill sequence modeled with an attention-based bidirectional LSTM survival network. Factorial analyses separated representation from model class. Results: C-index increased from 0.7113 with clinical factors alone to 0.7131 with PDC, 0.7273 with engineered summaries, and 0.7396 with the ordered sequence (ΔC=0.0283; 95% CI, 0.0189-0.0382). The sequence exceeded engineered summaries by 0.0123 (0.0040-0.0202). Richer representations improved discrimination by 0.0181-0.0191, approximately three times the 0.0059-0.0078 from changing model class. Among patients with PDC ≥0.80, PDC ranked risk poorly (C=0.4628), whereas sequence-model strata had 3-year event rates of 3.6%-22.8%. Discussion: A medication history's prognostic value lies in its temporal structure, which aggregate adherence measures discard, so the sequence advantage reflects preserved information rather than model complexity. External validation is needed. Conclusion: Traditional metrics of antihypertensive treatment conceal substantial risk heterogeneity, whereas a tokenized dispensing timeline recovers a prognostic treatment signature that improves cardiovascular risk prediction from existing records. Competing Interest Statement M.P.D. served on a one-time advisory board for Boehringer Ingelheim. Y.Z., K.B.F., A.B.C., K.N., and C.A.L. declare no competing interests. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board of the University of Michigan Medical School gave ethical approval for this work (HUM00244597), with a waiver of informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The electronic health record and pharmacy dispensing data analyzed in this study are not publicly available because they contain protected health information and their use is governed by the University of Michigan Medical School Institutional Review Board approval (HUM00244597) and by the agreements under which they were obtained. De-identified analytic datasets are available to only qualified researchers from the corresponding author on reasonable request, subject to institutional approval and a data-use agreement. Funder Information Declared Rackham Graduate School, University of Michigan , Rackham Predoctoral Fellowship Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 07, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Digital Treatment Signatures: Cardiovascular Risk Prediction Using Antihypertensive Medication Fill History Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Digital Treatment Signatures: Cardiovascular Risk Prediction Using Antihypertensive Medication Fill History Yifan Zheng , Karen B. Farris , Antoinette B. Coe , Michael P. Dorsch , Kayvan Najarian , Corey A. Lester medRxiv 2026.09.03.26362175; doi: https://doi.org/10.64898/2026.09.03.26362175 Share This Article: Copy Citation Tools Digital Treatment Signatures: Cardiovascular Risk Prediction Using Antihypertensive Medication Fill History Yifan Zheng , Karen B. Farris , Antoinette B. Coe , Michael P. Dorsch , Kayvan Najarian , Corey A. Lester medRxiv 2026.09.03.26362175; doi: https://doi.org/10.64898/2026.09.03.26362175 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (616) Allergy and Immunology (897) Anesthesia (328) Cardiovascular Medicine (4781) Dentistry and Oral Medicine (476) Dermatology (411) Emergency Medicine (646) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1617) Epidemiology (15865) Forensic Medicine (32) Gastroenterology (1196) Genetic and Genomic Medicine (7006) Geriatric Medicine (728) Health Economics (1060) Health Informatics (5007) Health Policy (1429) Health Systems and Quality Improvement (1747) Hematology (583) HIV/AIDS (1338) Infectious Diseases (except HIV/AIDS) (16258) Intensive Care and Critical Care Medicine (1164) Medical Education (665) Medical Ethics (151) Nephrology (721) Neurology (7216) Nursing (366) Nutrition (1074) Obstetrics and Gynecology (1234) Occupational and Environmental Health (1002) Oncology (3584) Ophthalmology (1044) Orthopedics (395) Otolaryngology (448) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1784) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5851) Public and Global Health (9716) Radiology and Imaging (2399) Rehabilitation Medicine and Physical Therapy (1438) Respiratory Medicine (1245) Rheumatology (636) Sexual and Reproductive Health (769) Sports Medicine (577) Surgery (772) Toxicology (107) Transplantation (303) Urology (288)
## Related Clinical Research

- [Dyslipidemia care in Japan before and after the 2024 fee revision: nationwide claims analysis](https://medichelpline.com/clinical-feed/plos-one-19-real-world-patterns-of-dyslipidemia-care-before-and-after-a-national-fee.md)
- [Impact of Nighttime Light Exposure on Heart Health and Disease Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-nighttime-light-exposure-may-alter-the-heart-and-increase-disease-risk.md)
- [Genistein modifies the association between EASIX and estimated 10-year ASCVD risk](https://medichelpline.com/clinical-feed/plos-one-13-interaction-between-genistein-and-the-endothelial-activation-and-stress-index.md)
- [RACOVIR registry: Oral anticoagulation in primary care patients with non‑valvular atrial fibrillat](https://medichelpline.com/clinical-feed/medrxiv-1-oral-anticoagulation-registry-in-patients-with-atrial-fibrillation-treated-in.md)
- [Subjective Oral Status, Oral Health Behaviours, and History of Systemic Disease in Older Adults](https://medichelpline.com/clinical-feed/pubmed-42694012.md) (DOI: 10.3290/j.ohpd.c_2807)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.